The ongoing pandemic has only exacerbated racial and gender pay gaps across the board, according to Arjuna Capital and Proxy Impact’slatest scorecard. And while biopharma darling Pfizer scored itself an A on the pay equity front, it looks like Biogen’s report card could spell out even more trouble for the embattled biotech, which was one of 24 companies to receive an F.